secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091220
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent Biosciences Q2 2024 net loss $59.0M; cash $389.9M; trial enrollment on track for 2025 readouts
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities $389.9M as of June 30, 2024; expected to fund operations into 2027.
- Net loss $59.0M for Q2 2024, compared to $44.1M in Q2 2023; R&D expenses $54.3M.
- Enrollment in SUMMIT, PEAK, APEX registration-directed trials on track; topline results expected from all three in 2025.
- Appointed Cole Pinnow as Chief Commercial Officer; initiated IND-enabling studies for CNS-penetrant ErbB2 program.
- Plan to initiate Phase 1 trial for FGFR2 inhibitor in H2 2024; IND-enabling studies for PI3Ka program ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000095017024091220/0000950170-24-091220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000095017024091220/cogt-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer